Media.Player

DNA Methylation Biomarkers for Rare Circulating Cancer Cell Detection

Detailed Technology Description

None

Others

*Abstract

University of MissouriOffice of Technology Management & Industry RelationsNon-Confidential Abstract of InventionUM Disclosure No. 09UMC073 and O8UMC040Multiple Methylation Sensitive Enzyme Restriction PCR (MSR-PCR) is a highly sensitive and specific novel PCR assay, which is suitable for detection of rare cancer cells including circulating various tumor cells (CTCs) in blood. Emerging evidence indicates that the disseminating CTCs present in the peripheral blood and bone marrow represent an early rather than a late event in cancer development. Early detection of CTCs and characterization of the molecular signature of metastatic clones provide vital insight information for early diagnosis. Furthermore, monitoring CTCs during the entire course of treatment, especially after surgical resection and chemotherapy, provides objective information for personalized clinical management to avoid unnecessary therapeutic related toxicity. A universal cancer diagnostic kit for detection of occult circulating tumor cells (CTCs) at early state of cancer development can be generated from our newly developed MSR-PCR conjugated a panel of tumor-specific DNA methylation biomarkers disclosed in this invention. Detectible malignancies include hematopoietic tumors (leukemia, lymphoma, myelodysplastic syndrome, multiple myeloma), carcinoma (breast cancer, colorectal cancer, prostate cancer, ovarian cancer and lung cancer) and melanoma.POTENTIAL AREAS OF APPLICATION:• Preventive medicine, Cancer screening, Oncology, Chemotherapy, personalized cancer therapyMAIN ADVANTAGES OF INVENTION:• Monitoring responses to therapies during cancer treatment and early prediction of relapses • Either a gel-based regular PCR or real-time PCR format • Cost effective and easily adaptable in most molecular diagnostic laboratories• Different types of specimens such as whole blood, cellular fraction or plasma, bone marrow aspirate, dried slides, and other biofluids can be used • DNA is chemically stable as starting material• Bisulfite treatment of DNA is unnecessaryREFERENCE:• Wang et al., (2010) Int. J. Clin. Exp. Path. 3:265-279.PATENT STATUS:• 12/383,790 pending; continuation in preparation.INVENTOR(S): Wang, Shi, Taylor, Caldwell, and NalluriCONTACT INFO:Paul Hippenmeyer, Sr. Licensing & Business Development AssociateOffice of Technology Management and Industry RelationsEmail: hippenmeyerp@missouri.eduPhone: 573-882-0470

*Principal Investigator

Name: Michael Wang

Department:

Name: Charles Caldwell, Professor of Pathology and Anatomical Sciences

Department:

Name: Kristen Taylor

Department:

Name: Srilatha Nalluri

Department:

Name: Dali Zheng, Postdoctoral Research Fellow

Department:

Country/Region

USA